ArticleCancer research2022
Cardiac Dysfunction Promotes Cancer Progression via Multiple Secreted Factors.
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- Cardio-Oncology in Cold Climates: Epidemiological Features, Bidirectional Interaction Mechanisms, and Integrated Management Strategies.Cardiovascular toxicology · 2026Review
- The Inflammation-Mediated Bidirectional Relationship Between Cardiovascular Disease and Cancer.Diseases (Basel, Switzerland) · 2026Review
- Extracellular vesicles from hypertrophic cardiomyocytes promote breast cancer progression.Communications biology · 2026Article
- The role of angiotensin II in cardiovascular disease-induced cancer growth.Cardio-oncology (London, England) · 2026Article
- Cancer-driven cytokine immunomodulation ameliorates cardiac function and suppresses fibrosis.Journal of molecular and cellular cardiology plus · 2025Article
- Breast cancer progression in the presence of treated and untreated left ventricular dysfunction.Cardio-oncology (London, England) · 2025Article
- Evolving tumor microenvironment: Driving cancer initiation and progression in cardiovascular diseases.iScience · 2025Review
- Ischemic Injury Drives Nascent Tumor Growth Via Accelerated Hematopoietic Aging.JACC. CardioOncology · 2025Article
- Cancer and Cardiovascular Disease: Shared Risk Factors, Mechanisms, and Clinical Implications: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Bidirectional Interaction in Cardio-Oncology Toward Novel Therapeutic Strategies for Cardiovascular Diseases: JACC: CardioOncology Primer.JACC. CardioOncology · 2025Review
- Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.European journal of heart failure · 2025Review
- Insights Into Heart-Tumor Interactions in Heart Failure.Circulation research · 2025Review
- The crosstalk of breast cancer and ischemic heart disease.Cell death discovery · 2025Review
- Cardiovascular Disease and Cancer: A Dangerous Liaison.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Cancer Development and Progression in Patients with Heart Failure.Current heart failure reports · 2024Review
- Heart failure-induced microbial dysbiosis contributes to colonic tumour formation in mice.Cardiovascular research · 2024Article
- Article
- Current evidence regarding the cellular mechanisms associated with cancer progression due to cardiovascular diseases.Journal of translational medicine · 2024Review
- Cancer-Induced Resting Sinus Tachycardia: An Overlooked Clinical Diagnosis.Oncology reviews · 2024Review
- Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure and cancer are the leading cause of deaths worldwide. While heart failure and cancer have been considered separate diseases, it is becoming evident that they are highly connected and affect each other's outcomes. Recent studies using experimental mouse models have suggested that heart failure promotes tumor progression. The mouse models used involve major irreversible surgery. Here, we induced heart hypertrophy via expression of activating transcription factor 3 (ATF3) in cardiomyocytes, followed by cancer cells' implantation. Tumors developing in ATF3-transgenic mice grew larger and displayed a more highly metastatic phenotype compared with tumors in wild-type mice. To address whether ATF3 expression or the cardiac outcome are necessary for tumor progression, ATF3 expression was turned off after cardiac hypertrophy development followed by cancer cell implantation. The tumor promotion phenotype and the enhancement of metastatic properties were preserved, suggesting that the failing heart per se is sufficient to promote tumor progression. Serum derived from ATF3-transgenic mice enhanced cancer cell proliferation and increased cancer cell metastatic properties in vitro. Using a cytokine array panel, multiple factors responsible for promoting tumor cell proliferation and the metastatic phenotype were identified. Interestingly, the failing heart and the tumor separately and simultaneously contributed to higher levels of these factors in the serum as well as other tissues and organs. These data suggest the existence of intimate cross-talk between the hypertrophied heart and the tumor that is mediated by secreted factors, leading to cancer promotion and disease deterioration. SIGNIFICANCE: This work highlights the importance of early diagnosis and treatment of heart failure prior to reaching the irreversible stage that can exacerbate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.